Alemtuzumab gets a second bite

A
Alemtuzumab gets two bites of the cherry. #MSBlog #MSResearch


“The following press release from Genzyme indicates that the FDA will reassess alemtuzumab via a standard route rather than via an appeal process. Maybe MSers in the US will get access to this drug before the end of the year.”




CoI: multiple

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

1 comment

  • This is wonderful news as it allows the FDA to save face. I think the chances of Lemtrada getting a US license must now be very high. If it went to appeal the chances would have been much lower. Good news for people with MSers.

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives